Canadian Sciences Speakers Network

Réseau Canadien de Panélistes Scientifiques


Sylvie Mader: CSSN Speaker

Sylvie Mader

Montreal, Quebec

Position: Full Professor at UdeM – Institute for Research in Immunology and Cancer

Organization: Université de Montréal

After training at the École normale supérieure de Paris, the Université de Paris VI and at the Institut Pasteur, Sylvie Mader joined Pierre Chambon’s team at the Louis Pasteur Université in Strasbourg for a Ph.D. in Biochemistry in 1987, which she completed in 1991. She then joined Nahum Sonenberg’s team, at McGill University, for postdoctoral training where she brought to light a control mechanism of translation involving eIF4E. She joined the Université de Montréal in 1995 and was recruited in 2005 by the Institute for Research in Immunology and Cancer, where she heads the Molecular Targeting in Breast Cancer research unit.

Areas of Expertise:

+ Cancer
+ Transcription
+ Ubiquitination, SUMOylation

Language(s):

+ English
+ French


My Work

What I do:

Sylvie Mader and her team try to identify the causes of the diversity of mammary tumors and how they impact tumor responses to the drugs used in breast cancer treatment. The group strives to better understand drug resistance mechanisms and to identify new therapeutic targets and strategies to optimize breast cancer treatment.

Ask me about:

N/A

Why me:

N/A

Fun facts:

N/A


About Me

Sector: Academia (Post Secondary)

English proficiency: Read, Write, Speak

French proficiency: Read, Write, Speak

Pronouns: She/Her/Hers

Gender: Female

Demographic: European / White


Recent Publications

Title Year
EZH2 Inhibition Induces a Metabolic Stress Response, Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting2026
116eP The p53-Responsive lncRNA AC003088.1 Promotes Pro-Survival Phenotypes in Breast Cancer cells2026
A ZNF-nanobody fusion reveals SUMOylation-dependent changes in p53 protein localization2026
Dual Targeting of IDH2 and the Ubiquitin-Proteasome System Reveals a Functional Vulnerability in Breast Cancer Models2026
A short SUMOylation tag modulates transcription factor activity2025
CDADC1 is a vertebrate-specific dCTP deaminase that metabolizes gemcitabine and decitabine to prevent cellular toxicity2025
IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition2024
Design, synthesis and antiproliferative activity of raloxifene/histone deacetylase inhibitor hybrids in breast cancer2024
OR11-02 Structural Determinants of Pure Antiestrogenic Activity2023
The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens2022
CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA32022
Estrogens desensitize MCF-7 breast cancer cells to apelin-induced autophagy and enhanced growth under estrogen starvation: a possible implication in endocrine resistance2022
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells2022
Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat2021
Studying the Genomic Role of Cathepsin-D in ER+ Breast Cancer2021
Complex regulation of orphan nuclear receptor Nur77 (Nr4a1) transcriptional activity by SUMO2 and PIASγ2020
Cholesterol as an Endogenous Ligand of ERRα Promotes ERRα-Mediated Cellular Proliferation and Metabolic Target Gene Expression in Breast Cancer Cells2020
Isolation and functional characterization of a novel endogenous inverse agonist of estrogen related receptors (ERRs) from human pregnancy urine2019
Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells2018
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen – A new hybrid design paradigm2018
Monitoring ligand-dependent assembly of receptor ternary complexes in live cells by BRETFect2018
MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets2017
MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation2017
Single-cell profiling reveals that eRNA accumulation at enhancer–promoter loops is not required to sustain transcription2016
MHC class I–associated peptides derive from selective regions of the human genome2016